NCT02882282 2025-10-23
Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia
M.D. Anderson Cancer Center
Phase 2 Completed
M.D. Anderson Cancer Center
Astellas Pharma Inc
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology